We have ‘surrendered more to the machines’, says quant fund titan Cliff Asness

Unlock the Editor’s Digest for free Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Quant group AQR Capital Management is embracing artificial intelligence and machine learning techniques for trading decisions, ending years of reticence from one of the sector’s historic holdouts. The Connecticut-based hedge fund that has $136bn under … Read more

Should we diversify our investment portfolio?

Unlock the Editor’s Digest for free Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. We’re a middle-aged couple with three children and a heavily US-focused investment portfolio. How can we better diversify our holdings to reduce geographic risk? Neil Wilson, investor strategist at Saxo UK, says it’s a common … Read more

BlackRock removed from Texas blacklist after climate policy rollback

Unlock the Editor’s Digest for free Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Texas has removed BlackRock from a list of companies boycotted from receiving its investment funds, three years after the state targeted the world’s largest asset manager over its environmental policies. The decision by the state’s … Read more

Ex-Janus Henderson analyst part of greedy ‘secret trading club’, jury hears

Unlock the Editor’s Digest for free Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. A former Janus Henderson analyst and his associates were part of a “secret trading club” driven by greed that used insider information to earn profits of nearly £1mn, a London court has heard. Redinel Korfuzi … Read more

A Nasdaq high on Chinese herbs

Stay informed with free updates Simply sign up to the Capital markets myFT Digest — delivered directly to your inbox. Traditional Chinese medicine is so hot right now: Regencell is a Hong Kong-based/Cayman Islands-incorporated/Nasdaq-listed “early-stage” bioscience company that develops herb-based treatments for ADHD and autism spectrum disorder. Net losses reached $4.36mn and $6.06mn in the fiscal years … Read more